http://www.takeda.com/ Home http://www.takeda.com/ http://www.takeda.com/favicon.ico icon http://www.takeda.com/press/article_45034.html Osaka, Japan, February 09, 2012—Takeda Pharmaceutical Company Limited (“Takeda”) announced today the establishment of the Takeda Shanghai Development Center (“TSDC”) within the Shanghai-based Takeda (China) Holdings Co., Ltd. (“TCH”), which is a wholly owned subsidiary of Takeda. 2012-02-09T10:00:00+09:00 http://www.takeda.com/press/article_45028.html Deerfield, Ill., February 6, 2012 and Osaka, Japan, February 7, 2012 – Takeda Pharmaceutical Company Limited (Takeda) and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced EDARBYCLOR (azilsartan medoxomil and chlorthalidone) is now available by prescription in U.S. pharmacies for the treatment of hypertension to lower blood pressure in adults. It is the only fixed-dose therapy in the U.S. to combine an angiotensin II receptor blocker (ARB) with chlorthalidone in a once-daily, single tablet. In a phase 3 clinical trial, the systolic blood pressure reductions of the maximum dose of EDARBYCLOR (40/25 mg), by both clinic and trough 24-hour ambulatory blood pressure monitoring, were shown to be statistically superior to those of the fixed-dose combination of olmesartan medoxomil-hydrochlorothiazide at its maximum dose (40/25 mg). Additionally, similar blood pressure lowering effects of EDARBYCLOR were observed in a sub-group analysis of black patients. 2012-02-07T10:00:00+09:00 http://www.takeda.com/investor-information/quarterly-results/article_18140.html Presenters: Director, Chief Medical & Scientific Officer, Tadataka Yamada, M.D. [¥n] Senior Vice President, Finance & Accounting Department, Hiroshi Takahara 2012-02-01T15:00:00+09:00 http://www.takeda.com/press/article_45019.html Osaka, Japan, January 31, 2012 – Takeda Pharmaceutical Company Limited (“Takeda”) announced today that its Annual Report 2011 and CSR Data Book 2011 have received the special prize in the “Sustainability Reporting Award” section of the 15th Green Reporting Award and Sustainability Reporting Award, co-sponsored by Toyo Keizai Inc., and the Green Reporting Forum*. 2012-01-31T15:00:00+09:00 http://www.takeda.com/press/article_44988.html Osaka, Japan, Cambridge, Mass and Tokyo, Japan, January 27, 2012 – Takeda Pharmaceutical Company Limited (“Takeda”) and Millennium: The Takeda Oncology Company (“Millennium”) today announced that Takeda Bio Development Center Limited (“Takeda Bio”) has initiated enrollment of patients in Japan for the two ongoing global Phase III clinical trials for the anti-prostate cancer investigational agent, orteronel(TAK-700). 2012-01-27T15:00:00+09:00